T2 Biosystems (TTOO) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TTOO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTOO, but not buy additional shares or sell existing shares.
View TTOO analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 12 month target prices for T2 Biosystems' stock. Their TTOO share price forecasts range from $2.50 to $2.50. On average, they expect the company's share price to reach $2.50 in the next year. This suggests a possible upside of 3,068.6% from the stock's current price.
View analysts price targets for TTOO or view top-rated stocks among Wall Street analysts.

T2 Biosystems' stock was trading at $1.42 at the beginning of 2023. Since then, TTOO stock has decreased by 94.4% and is now trading at $0.0789.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our TTOO earnings forecast.

T2 Biosystems, Inc. (NASDAQ:TTOO) released its quarterly earnings results on Thursday, November, 4th. The medical equipment provider reported ($4.00) EPS for the quarter, hitting analysts' consensus estimates of ($4.00). The medical equipment provider earned $7.43 million during the quarter. During the same quarter in the prior year, the firm earned ($4.00) earnings per share.

Shares of T2 Biosystems reverse split on the morning of Thursday, October 13th 2022. The 1-50 reverse split was announced on Thursday, October 13th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT).

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

T2 Biosystems' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (3.70%), Hudson Bay Capital Management LP (3.21%), CVI Holdings LLC (2.71%), Anson Funds Management LP (2.59%), Anson Funds Management LP (2.59%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Adrian M Jones, Alec Barclay, Brett A Giffin, Goldman Sachs & Co Llc, John J Sperzel III, John M Sprague, John Mcdonough and Michael Terrence Gibbs.
View institutional ownership trends.

Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TTOO stock can currently be purchased for approximately $0.08.

T2 Biosystems (NASDAQ:TTOO) has a market capitalization of $1.96 million and generates $22.31 million in revenue each year.

The company employs 158 workers across the globe.

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The official website for the company is www.t2biosystems.com. The medical equipment provider can be reached via phone at (781) 761-4646, via email at ir@t2biosystems.com, or via fax at 781-357-3080.